The Clinical and Research Support Core will be the focal point of much of the activity in the Alzheimer's Disease Research Center (ADRC). This Core will be responsible for the recruitment and characterization of cognitively impaired subjects and normal control individuals in both Rochester, MN and Jacksonville, FL. In Rochester, patients will be derived from community and regional resources and control subjects will be recruited from the community. In Jacksonville, African American and indigent cognitively impaired subjects and a normal control cohort of American-American subjects will be established as well. Most of the these activities will be a continuation of current practices in the Mayo Alzheimer's Disease Center. The cognitively impaired and normal control subjects at both sites will be evaluated in an identical fashion and all of the data will be entered into a common database. The subjects will be screened for a variety of research projects including epidemiology, natural history, neuropsychology, neuroimaging, investigational drug trials, predictor studies, neuropathology and genetic studies. The individuals recruited will be used to address the scientific themes of the ADRC: neuroepidemiology of aging and dementia, boundary between normal aging and very early cognitive impairment, and predictors of cognitive deterioration. A mechanism is in place for longitudinal follow-up of all of these subjects. The Clinical and Research Support Core will also continue the development and maintenance of a centralized database. The database has been created for clinical, neuropsychological, neuroimaging and neuropathology data from Rochester and Jacksonville and this database will be expanded. Quality control measures are in place for the maintenance for the database and programming capabilities are available for modifications. The Core will also serve the ADRC consultation expertise in epidemiology and biostatistics.
| Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872 |
| Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064 |
| Jack Jr, Clifford R; Wiste, Heather J; Schwarz, Christopher G et al. (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517-1528 |
| Jung, Youngsin; Jordan 3rd, Lennon G; Lowe, Val J et al. (2018) Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 5:376-381 |
| Townley, Ryan A; Botha, Hugo; Graff-Radford, Jonathan et al. (2018) 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin 18:897-902 |
| Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10: |
| Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43 |
| Arnold Fiebelkorn, Catherine; Vemuri, Prashanthi; Rabinstein, Alejandro A et al. (2018) Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clin Proc 93:300-306 |
| Baker, Darren J; Petersen, Ronald C (2018) Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 128:1208-1216 |
| Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10 |
Showing the most recent 10 out of 1014 publications
